Malik Richard, Lessels Naomi S, Webb Sarah, Meek Mirim, Graham Paul Gotis, Vitale Carlo, Norris Jacqueline M, Power Helen
Faculty of Veterinary Science, The University of Sydney, NSW 2006, Australia.
J Feline Med Surg. 2009 Jan;11(1):40-8. doi: 10.1016/j.jfms.2008.11.012.
Feline herpesvirus 1 (FHV-1) is a common cause of ocular and upper respiratory disease in cats and kittens, and a potential cause of eosinophilic dermatitis.
The systemic anti-herpes drug, famciclovir (Famvir; Novartis), would be effective in the clinical management of disease attributable to FHV-1, including conjunctivitis, keratitis, corneal sequestra, rhinosinusitis and FHV-1 associated dermatitis.
Oral famciclovir was used to treat signs considered referable to FHV-1 in 10 cats: four had primary ocular disease, two had rhinosinusitis and four had FHV-1 associated dermatitis. Patients treated in Australia (five cats) and Europe (one cat) were given 62.5 mg of famciclovir once or twice daily. Four cats treated in the USA were given 125 mg three times daily. Famciclovir was uniformly well tolerated and, in all cases, had a positive impact on the patient's condition. The apparent improvement in lesions was superior to what had been achieved previously using other therapeutic strategies. One cat with severe destructive rhinosinusitis was significantly improved by a 4-month course of famciclovir in combination with antibacterials. Corneal sequestra detached in two out of three cats treated; cats with ocular signs were qualitatively more comfortable, with reduced clinical signs and an improved appearance of the eyes. Critically, oral famciclovir therapy was considered more convenient than topical ocular therapy. All four cats with FHV-1 associated dermatitis improved substantially, although relapse occurred subsequently in three patients. A further cat with presumptive FHV-1 associated dermatitis responded to topical aciclovir cream before famciclovir could be sourced.
Famciclovir appears to be a promising systemic drug for treating diseases associated with FHV-1 infection. More rigorous clinical trials are required to optimise the dosing regimen for safe and effective specific anti-herpes treatment in feline clinical medicine.
猫疱疹病毒1型(FHV-1)是猫和小猫眼部及上呼吸道疾病的常见病因,也是嗜酸性粒细胞性皮炎的潜在病因。
全身性抗疱疹药物泛昔洛韦(Famvir;诺华公司)对FHV-1所致疾病的临床治疗有效,包括结膜炎、角膜炎、角膜翳、鼻窦炎及FHV-1相关性皮炎。
口服泛昔洛韦用于治疗10只猫中被认为与FHV-1相关的症状:4只患有原发性眼部疾病,2只患有鼻窦炎,4只患有FHV-1相关性皮炎。在澳大利亚治疗的患者(5只猫)和欧洲治疗的患者(1只猫),给予62.5毫克泛昔洛韦,每日一次或两次。在美国治疗的4只猫,给予125毫克,每日三次。泛昔洛韦耐受性良好,在所有病例中,对患者病情均有积极影响。病变的明显改善优于之前使用其他治疗策略所取得的效果。一只患有严重破坏性鼻窦炎的猫,在接受4个月的泛昔洛韦联合抗菌药物治疗后有显著改善。三只接受治疗的猫中有两只角膜翳脱落;有眼部症状的猫在定性上感觉更舒适,临床症状减轻,眼睛外观改善。至关重要的是,口服泛昔洛韦治疗被认为比局部眼部治疗更方便。所有4只患有FHV-1相关性皮炎的猫都有显著改善,尽管随后有3只患者复发。在获取泛昔洛韦之前,另一只疑似FHV-1相关性皮炎的猫对局部使用阿昔洛韦乳膏有反应。
泛昔洛韦似乎是一种有前景的全身性药物,用于治疗与FHV-1感染相关的疾病。需要更严格的临床试验来优化给药方案,以便在猫科临床医学中进行安全有效的特异性抗疱疹治疗。